3 Tech Stocks Ready for Post-Earnings Growth

Credits: Canva

By: Aquib Nawab


In today's market, trillion-dollar valuations have become more common. Only a handful of companies have reached this real-money status. Trillion-dollar valuations signify dominance and influence.


Credits: Canva

Broadcom (NASDAQ: AVGO), a leading semiconductor company with a current valuation of $550 billion, aims to join the trillion-dollar club by harnessing the power of artificial intelligence (AI) and the recent acquisition of VMWare will impact software revenue.

1 - Broadcom

Credits: Bloomberg

Broadcom - AI's Contribution

Generative AI has had a significant impact on Broadcom's revenue, representing close to $1.5 billion in the fourth quarter or 20% of total semiconductor revenue. Demand for AI accelerators from hyperscalers should drive networking revenue 30% higher in 2024.

Credits: Data Center Knowledge

Apple plays a crucial role in contributing to Broadcom's revenue. A multiyear, multibillion-dollar agreement focuses on 5G components. Apple accounted for 20% of all Broadcom revenue in 2022 and 2023.

Broadcom - Apple Partnership

Credits: Ciosea

JPMorgan Chase (NYSE: JPM), currently valued at $504 billion, is on the path to becoming a trillion-dollar bank, thanks to its stability and strategic financial practices.

2 - JPMorgan Chase

Credits: Seeking Alpha

JPMorgan Chase - Interest Rate Environment

The impact of the high-interest rate environment on JPMorgan's performance, benefiting from greater net interest income. Most analysts anticipate three rate cuts at most.

Credits: Arch Daily

JPMorgan's historical role as a stable institution in times of financial uncertainty. It held $3.9 trillion in assets at the end of 2023, solidifying its position as the biggest, most valuable financial institution.

JPMorgan Chase - Stability

Credits: CNN

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical giant valued at $511 billion, is poised to reach the trillion-dollar milestone, driven by its innovative diabetes and obesity therapies.

3 - Novo Nordisk

Credits: Pharmaceutical Technology

Novo Nordisk - Glucagon-Like Peptide-1 Therapies

The success of Wegovy and Ozempic in boosting sales, with Ozempic sales surging 66% and Wegovy showing 420% gains. Novo Nordisk expects revenue to grow by as much as 26% this year with operating profits surging 29% higher.

Credits: Novo Nordisk Gulf

Challenges in meeting the high demand for Novo Nordisk's products, leading to a commitment to spending nearly $9 billion in new capacity. The stock completed a 2-for-1 stock split in September.

Novo Nordisk - Capacity Expansion

Credits: Seeking Alpha

3 big banking stocks that just got upgraded